Physician profile
Ruby Gupta
NPI 1669707402
$2,628.30
in general payments reported to CMS, 2019-2025
34 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.34 · 2022: $434 · 2024: $582 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048 · Education: $66.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.44 |
| Education | $66.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $278.15 | 2022-2025 | Venclexta, Tecentriq, Itovebi |
| Incyte Corporation | $210.30 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Novartis Pharmaceuticals Corporation | $208.48 | 2022-2025 | |
| Janssen Biotech, INC. | $202.56 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| Gilead Sciences, INC. | $135.23 | 2025 | Trodelvy |
| Lilly USA, LLC | $123.05 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $116.16 | 2022-2024 | |
| Daiichi Sankyo INC. | $114.27 | 2024-2025 | Enhertu, Vanflyta |
| Celgene Corporation | $110.89 | 2024-2025 | Reblozyl, Opdivo, Pomalyst |
| Amgen INC. | $95.94 | 2022 | |
| Jazz Pharmaceuticals INC. | $90.54 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $87.30 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Pharmaessentia USA Corporation | $82.14 | 2025 | Besremi |
| Beone Medicines USA, INC. | $81.75 | 2025 | Brukinsa |
| Legend Biotech USA INC. | $74.56 | 2025 | Carvykti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $62.27 | 2025 | Ojjaara, Blenrep |
| Beigene USA, INC. | $57.75 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $53.90 | 2025 | Orgovyx |
| Tersera Therapeutics LLC | $53.07 | 2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $49.86 | 2024-2025 | Libtayo |
| Eisai INC. | $43.68 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $33.02 | 2025 | |
| Alexion Pharmaceuticals, INC. | $32.12 | 2019 | |
| Blueprint Medicines Corporation | $30.99 | 2025 | Ayvakit |
| Genzyme Corporation | $27.09 | 2025 | |
| Pfizer INC. | $24.64 | 2025 | |
| Genmab U.S., INC. | $23.41 | 2025 | Epkinly |
| Ipsen Biopharmaceuticals, INC | $20.53 | 2025 | Onivyde |
| Kite Pharma, INC. | $18.77 | 2019 | |
| Array Biopharma INC | $18.43 | 2025 | Mektovi, Braftovi, Lorbrena |
| Pharmaand Gmbh | $17.97 | 2025 | Rubraca |
| Tolmar, INC. | $17.97 | 2025 | Rubraca |
| Sobi, INC | $16.58 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.